Skip to main content

BRCA1/2 mutation carriers & risk reducing mastectomy: Who undergoes surgery and potential benefits.

Publication ,  Journal Article
Record, SM; Thomas, SM; Ntowe, K; Chiba, A; Plichta, JK
Published in: Am J Surg
January 2024

BACKGROUND: Risk-reducing mastectomy (RRM) is the most effective breast cancer risk-reduction strategy in BRCA1/2 mutation carriers. We examined factors associated with RRM and its relationship with overall survival (OS). METHODS: Patients aged 18-80y at diagnosis of their BRCA1/2 mutation were selected from our institutional database and stratified by RRM receipt. Differences were tested; unadjusted OS was estimated. RESULTS: Of the 306 patients, median age was 43y; median follow-up was 41.6mo. Patients undergoing RRM were more often married with a history of pregnancy (both p ​≤ ​0.05). Of female patients, 23.1% underwent RRM. Two patients had malignancy detected at RRM, and one developed breast cancer after RRM. Higher unadjusted OS was observed with RRM (p ​= ​0.02). CONCLUSIONS: Our analyses suggest that family-structure may play a role in a patient's decision to undergo RRM. We also demonstrated RRM is likely associated with improved survival, potentially underscoring the importance of this option for BRCA1/2 mutation carriers.

Duke Scholars

Published In

Am J Surg

DOI

EISSN

1879-1883

Publication Date

January 2024

Volume

227

Start / End Page

146 / 152

Location

United States

Related Subject Headings

  • Surgery
  • Mutation
  • Mastectomy
  • Humans
  • Heterozygote
  • Genes, BRCA2
  • Female
  • Breast Neoplasms
  • BRCA2 Protein
  • BRCA1 Protein
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Record, S. M., Thomas, S. M., Ntowe, K., Chiba, A., & Plichta, J. K. (2024). BRCA1/2 mutation carriers & risk reducing mastectomy: Who undergoes surgery and potential benefits. Am J Surg, 227, 146–152. https://doi.org/10.1016/j.amjsurg.2023.10.011
Record, Sydney M., Samantha M. Thomas, Koumani Ntowe, Akiko Chiba, and Jennifer K. Plichta. “BRCA1/2 mutation carriers & risk reducing mastectomy: Who undergoes surgery and potential benefits.Am J Surg 227 (January 2024): 146–52. https://doi.org/10.1016/j.amjsurg.2023.10.011.
Record SM, Thomas SM, Ntowe K, Chiba A, Plichta JK. BRCA1/2 mutation carriers & risk reducing mastectomy: Who undergoes surgery and potential benefits. Am J Surg. 2024 Jan;227:146–52.
Record, Sydney M., et al. “BRCA1/2 mutation carriers & risk reducing mastectomy: Who undergoes surgery and potential benefits.Am J Surg, vol. 227, Jan. 2024, pp. 146–52. Pubmed, doi:10.1016/j.amjsurg.2023.10.011.
Record SM, Thomas SM, Ntowe K, Chiba A, Plichta JK. BRCA1/2 mutation carriers & risk reducing mastectomy: Who undergoes surgery and potential benefits. Am J Surg. 2024 Jan;227:146–152.

Published In

Am J Surg

DOI

EISSN

1879-1883

Publication Date

January 2024

Volume

227

Start / End Page

146 / 152

Location

United States

Related Subject Headings

  • Surgery
  • Mutation
  • Mastectomy
  • Humans
  • Heterozygote
  • Genes, BRCA2
  • Female
  • Breast Neoplasms
  • BRCA2 Protein
  • BRCA1 Protein